JP2021506923A5 - - Google Patents

Download PDF

Info

Publication number
JP2021506923A5
JP2021506923A5 JP2020534509A JP2020534509A JP2021506923A5 JP 2021506923 A5 JP2021506923 A5 JP 2021506923A5 JP 2020534509 A JP2020534509 A JP 2020534509A JP 2020534509 A JP2020534509 A JP 2020534509A JP 2021506923 A5 JP2021506923 A5 JP 2021506923A5
Authority
JP
Japan
Prior art keywords
indole
isopropyl
methylpyridine
ethyl
dimethoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020534509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506923A (ja
JP7313354B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/066106 external-priority patent/WO2019126081A1/en
Publication of JP2021506923A publication Critical patent/JP2021506923A/ja
Publication of JP2021506923A5 publication Critical patent/JP2021506923A5/ja
Application granted granted Critical
Publication of JP7313354B2 publication Critical patent/JP7313354B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020534509A 2017-12-19 2018-12-18 Tlr阻害剤として有用なアミド置換されたインドール化合物 Active JP7313354B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607388P 2017-12-19 2017-12-19
US62/607,388 2017-12-19
PCT/US2018/066106 WO2019126081A1 (en) 2017-12-19 2018-12-18 Amide substituted indole compounds useful as tlr inhibitors

Publications (3)

Publication Number Publication Date
JP2021506923A JP2021506923A (ja) 2021-02-22
JP2021506923A5 true JP2021506923A5 (https=) 2022-01-11
JP7313354B2 JP7313354B2 (ja) 2023-07-24

Family

ID=65003571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534509A Active JP7313354B2 (ja) 2017-12-19 2018-12-18 Tlr阻害剤として有用なアミド置換されたインドール化合物

Country Status (14)

Country Link
US (1) US11420973B2 (https=)
EP (1) EP3728221B1 (https=)
JP (1) JP7313354B2 (https=)
KR (1) KR102755258B1 (https=)
CN (1) CN111511730B (https=)
AU (1) AU2018392316B2 (https=)
BR (1) BR112020011979A2 (https=)
CA (1) CA3085346A1 (https=)
EA (1) EA202091483A1 (https=)
ES (1) ES2922174T3 (https=)
IL (1) IL275353A (https=)
MX (1) MX2020005515A (https=)
SG (1) SG11202005700SA (https=)
WO (1) WO2019126081A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
BR112020011984A2 (pt) * 2017-12-20 2020-11-17 Bristol-Myers Squibb Company compostos de amino indol úteis como inibidores de tlr
CA3085942A1 (en) * 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
KR20210018818A (ko) 2018-06-05 2021-02-18 에프. 호프만-라 로슈 아게 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물
EP3807270B1 (en) 2018-06-12 2023-09-13 F. Hoffmann-La Roche AG Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
WO2020048583A1 (en) 2018-09-04 2020-03-12 F. Hoffmann-La Roche Ag Benzothiazole compounds for the treatment of autoimmune diseases
WO2020048595A1 (en) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel cyclic amidine compounds for the treatment of autoimmune disease
JP7367004B2 (ja) 2018-09-06 2023-10-23 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のための新規のピラゾロビリジン化合物
US12421240B2 (en) 2019-10-31 2025-09-23 Hoffmann-La Roche Inc. Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
JP7652772B2 (ja) * 2019-11-01 2025-03-27 ブリストル-マイヤーズ スクイブ カンパニー 置換ピラゾール化合物
JP2023502087A (ja) 2019-11-19 2023-01-20 エフ.ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロ-1H-ピロロ[1,2-a]ピラジン化合物
JP7649306B2 (ja) 2019-11-20 2025-03-19 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのスピロ(イソベンゾフラナゼチジン)化合物
CN115052860B (zh) * 2020-01-30 2024-06-21 艾尼莫生物科技公司 胶原蛋白1翻译抑制剂和其使用方法
EP4192588A1 (en) * 2020-08-04 2023-06-14 F. Hoffmann-La Roche AG Imidazo[1,2-a]pyridine compounds for the treatment of autoimmune disease
AR123281A1 (es) 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9
AR123286A1 (es) 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos de benzimidazol sustituidos útiles como inhibidores de tlr9
AU2021328577A1 (en) 2020-08-19 2023-03-23 Bristol-Myers Squibb Company 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
KR20240066957A (ko) 2022-10-31 2024-05-16 아주대학교산학협력단 자기염증질환 치료 및 예방 조성물
WO2026002036A1 (zh) * 2024-06-26 2026-01-02 北京双鹤润创科技有限公司 一种化合物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
HUP0104987A3 (en) 1998-12-18 2002-09-30 Axys Pharmaceuticals Inc South Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DK1474425T3 (da) 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
FR2854159B1 (fr) 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
MXPA05013922A (es) 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
WO2007115306A2 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008065198A1 (en) 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
DK2294065T3 (da) 2008-01-22 2014-04-28 Vernalis R&D Ltd Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8354400B2 (en) * 2008-09-26 2013-01-15 Eisai R&D Co., Ltd. Benzoxazole compounds and methods of use
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
NO2453895T3 (https=) 2009-07-16 2018-10-20
BR112012006630A2 (pt) 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
DK2663555T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
EP3208263A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
JP6184423B2 (ja) 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
SG10202103278TA (en) 2013-10-14 2021-04-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
EP3080124A1 (en) 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
HRP20210927T1 (hr) 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
EP3183251A4 (en) 2014-08-22 2017-12-27 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
KR102519535B1 (ko) 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물

Similar Documents

Publication Publication Date Title
JP2021506923A5 (https=)
JP2021506858A5 (https=)
US11420973B2 (en) Amide substituted indole compounds useful as TLR inhibitors
US11420958B2 (en) Aryl and heteroaryl substituted indole compounds
JP5690823B2 (ja) Jak受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
JP2021506816A5 (https=)
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
JP2021506889A5 (https=)
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
AU2015261812B2 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
CN111448190A (zh) 取代的吲哚化合物
JP2021506941A5 (https=)
JP2021507912A5 (https=)
RU2010139566A (ru) Пирролопиразиновые ингибиторы киназы
JP2005508932A5 (https=)
JP2012519678A5 (https=)
JP2014506929A5 (https=)
FI3436461T3 (fi) Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
JP2014521711A5 (https=)
RU2005127335A (ru) Новые производные цикломочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
JP2018525377A5 (https=)
JP7716993B2 (ja) Jakキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用
JP2019502680A5 (https=)
WO2018166993A2 (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
AU2017324281A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof